Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.

Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, Bassendine M, Main J, Thomas H.

Gut. 2006 Sep;55(9):1332-8. Epub 2005 Jun 30.

2.

Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.

Wright M, Grieve R, Roberts J, Main J, Thomas HC; UK Mild Hepatitis C Trial Investigators.

Health Technol Assess. 2006 Jul;10(21):1-113, iii.

3.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

4.

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB; German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group.

Gut. 2003 Mar;52(3):425-32.

5.

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.

Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A, Cooksley G, Klaskala W, Pettit K, Patel KK, Green J.

Am J Gastroenterol. 2004 Aug;99(8):1490-6.

PMID:
15307866
6.

Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.

Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, Patel KK, Green J.

Pharmacoeconomics. 2004;22(4):257-65.

PMID:
14974875
7.

Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.

Turnes J, Romero-Gómez M, Planas R, Solà R, García-Samaniego J, Diago M, Crespo J, Calleja JL, Rubio-Terrés C, Ventayol P.

Gastroenterol Hepatol. 2013 Nov;36(9):555-64. doi: 10.1016/j.gastrohep.2013.08.003. Epub 2013 Oct 9.

PMID:
24119723
8.

Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice.

Grishchenko M, Grieve RD, Sweeting MJ, De Angelis D, Thomson BJ, Ryder SD, Irving WL; Trent HCV Study Group.

Int J Technol Assess Health Care. 2009 Apr;25(2):171-80. doi: 10.1017/S0266462309090229. Epub 2009 Mar 31.

PMID:
19331708
9.
10.

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.

Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ.

JAMA. 2003 Jul 9;290(2):228-37.

PMID:
12851278
11.

Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N.

Health Technol Assess. 2007 Mar;11(11):1-205, iii. Review.

12.

The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.

Hartwell D, Cooper K, Frampton GK, Baxter L, Loveman E.

Health Technol Assess. 2014 Oct;18(65):i-xxii, 1-202. doi: 10.3310/hta18650. Review.

13.

Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.

Siebert U, Sroczynski G, Aidelsburger P, Rossol S, Wasem J, Manns MP, McHutchison JG, Wong JB.

Pharmacoeconomics. 2009;27(4):341-54. doi: 10.2165/00019053-200927040-00006.

PMID:
19485429
14.

Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.

Visconti AJ, Doyle JS, Weir A, Shiell AM, Hellard ME.

J Gastroenterol Hepatol. 2013 Apr;28(4):707-16. doi: 10.1111/jgh.12041.

PMID:
23173753
15.

Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.

Blázquez-Pérez A, San Miguel R, Mar J.

Pharmacoeconomics. 2013 Oct;31(10):919-31. doi: 10.1007/s40273-013-0080-3.

PMID:
24000086
16.
17.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

19.

Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations.

Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M.

Hepatology. 2012 Jan;55(1):49-57. doi: 10.1002/hep.24656. Epub 2011 Dec 6.

PMID:
21898506
20.

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.

Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD.

Ann Intern Med. 2012 Feb 21;156(4):279-90. doi: 10.7326/0003-4819-156-4-201202210-00005.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk